Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India

Investigation of an Antibody for RSV in Young Children

Recruiting
24 months or below
All
Phase 4
110 participants needed
1 Location

Study Overview

The purpose of this study is to describe the safety and efficacy outcomes associated with the use of nirsevimab, administered as per routine clinical practice, in neonates and infants aged 0 to 12 months born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Study Details

Study duration: up to 16 months, including 10 months of enrollment and 6 months of follow-up

  • Treatment duration: 1 day; 1 intramuscular (IM) injection
  • Visit frequency:
  • 1 in-person visit for immunization (Visit [V] 01) at Day (D) 1.
  • 3 phone call visits (V2, V3 and V4) at D31 (+ 14 days), D91 (+ 14 days) and D181 (+14 days) respectively.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: RSV Immunization
  • Age: 24 months or below
  • Gender: All

Inclusion Criteria: - Neonates and infants aged 0 to 12 months on the day of inclusion and born during or entering their first RSV season OR children up to 24 months of age on the day of inclusion who remain vulnerable to severe RSV disease through their second RSV season

Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:

  • Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Known thrombocytopenia, as reported by the parent(s)/legally acceptable representative(s), contraindicating intramuscular injection
  • Known bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Active LRTI on the day of study intervention administration
  • Active RSV infection on the day of study intervention administration
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
  • Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine in the same RSV season than inclusion in the study
  • Mother of the participant was administered an RSV vaccine during her pregnancy with the participant
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Receipt of any investigational drug in the last 30 days prior to the inclusion in the study
  • Participation at the time of study enrollment or in the 4 weeks preceding the study intervention administration or planned participation during the present study period, in another clinical study investigating a vaccine, drug, medical device, or medical procedure Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Updated on 19 Aug 2025. Study ID: NCT07109297

This study investigates the effects of an investigational monoclonal antibody on respiratory syncytial virus (RSV) in children. RSV is a common virus that affects the respiratory tract, particularly in young children. This study focuses on neonates and infants up to 12 months old during their first RSV season, as well as children up to 24 months old who are still at risk during their second RSV season.

Participants will receive an intramuscular injection of the investigational antibody. Following this, there will be three follow-up phone calls to monitor the participants' health and any reactions to the treatment. The study aims to gather data on the safety and efficacy of the antibody in preventing severe RSV disease.

  • Who can participate: Neonates and infants aged 0 to 12 months entering their first RSV season, or children up to 24 months who are vulnerable to severe RSV disease in their second season, can participate. Exclusions include hypersensitivity to study components, bleeding disorders, or recent receipt of certain medications or other RSV treatments.
  • Study details: Participants will receive one intramuscular injection of the investigational antibody. Follow-up will include three phone call check-ins to assess health and any reactions. The study will not involve any changes to the participants' usual medical care.
  • Study timelines and visits: The study will last up to 16 months. The study requires 1 visits.

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language